Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab After Stem Cell Transplantation for Relapsed/Refractory Multiple Myeloma
NCT04635735Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2020
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2020; status: terminated.
02
Drugs
ipilimumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04635735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04635735.